STOCK TITAN
  1. Home
  2. News
  3. DHR

Danaher Corporation - DHR STOCK NEWS

Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.

Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.

Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.

Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.

Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.

Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.

Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.

Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.

News

Danaher to Acquire Abcam

Rhea-AI Summary
Danaher Corporation to acquire Abcam for $5.7 billion in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
acquisition
-
News

Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock

Rhea-AI Summary
Danaher Corporation expects to complete the separation of Veralto Corporation on September 30, 2023. Danaher stockholders will receive one share of Veralto common stock for every three shares of Danaher common stock they hold on the Record Date. Fractional shares of Veralto common stock will be sold in the open market. No action is required by Danaher stockholders to receive the distributed shares of Veralto common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
dividends
-
News

Danaher Releases 2023 Sustainability Report

Rhea-AI Summary
Danaher Corporation has published its 2023 Sustainability Report, highlighting the company's sustainability program and achievements. The report details key accomplishments in product innovation, team building, and environmental protection. Danaher updated its product development tools to consider sustainability needs, increased diversity in its workforce, maintained pay equity, and developed tools to reduce greenhouse gas emissions. The company also assessed the sustainability practices of its suppliers and aims to increase coverage in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
News

BetterInvesting™ Magazine Update on Danaher Corp. and Alphabet Inc.

Rhea-AI Summary
Danaher Corp. (NYSE: DHR) has been named the 'Stock to Study' and Alphabet Inc. (NASDAQ: GOOG) as the 'Undervalued Stock' by the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine. This announcement highlights the importance of quarterly earnings presentations and the use of the BetterInvesting Stock Selection Guide for assessing a company's sales, earnings, and profitability. Investors can find more details in the October 2023 issue of BetterInvesting Magazine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
none
-
News

Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

Rhea-AI Summary
Beckman Coulter unveils the DxI 9000 Access Immunoassay Analyzer, a clinical diagnostics tool that addresses laboratory demands for speed, reliability, reproducibility, quality, and menu expansion. The analyzer has the capability to develop sensitive and clinically relevant assays, providing new opportunities to quantify trace amounts of biomarkers in blood samples. The collaboration with Fujirebio will support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in neurodegenerative diseases. The DxI 9000 also excels in improving clinical laboratory operations with zero daily maintenance requirements and automated safeguards to prevent erroneous reporting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
none
-
News

Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Rhea-AI Summary
Beckman Coulter Diagnostics has received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer. The analyzer is designed for small-to-medium-sized laboratories and uses standardized assays and reagents across Beckman Coulter's portfolio of AU clinical chemistry analyzers. It has a broad menu of 120-plus assays and has been independently verified for quality performance. Diagnostic testing guides 70% of medical decisions, and the DxC 500 AU Chemistry Analyzer aims to improve accuracy and reliability of results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
clinical trial
News

Danaher Reports Second Quarter 2023 Results

Rhea-AI Summary
Danaher Corporation (NYSE: DHR) announced its second quarter 2023 results, reporting a net earnings of $1.1 billion, or $1.49 per diluted common share, and a non-GAAP adjusted diluted net earnings per common share of $2.05. Revenues decreased 7.5% year-over-year to $7.2 billion, with a 7.0% non-GAAP core revenue decrease. Operating cash flow for the quarter was $1.9 billion, and non-GAAP free cash flow was $1.6 billion. The Company anticipates low-single digits year-over-year decrease in non-GAAP base business core revenue for the third quarter 2023, and low-single digits year-over-year growth for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
-
News

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics

Rhea-AI Summary
Fujirebio (ticker: FUJI) and Beckman Coulter announced a partnership to develop blood-based neurodegenerative disease assays, addressing the global unmet clinical need for Alzheimer's Disease diagnostics. With over 100 drug candidates under development, the partnership aims to accelerate the deployment of new biomarkers to laboratories and clinicians worldwide, leveraging Beckman Coulter's high-sensitivity immunoassay analyzers and Fujirebio's assay technology. The collaboration will focus on menu expansion on Beckman Coulter’s Access Family of Immunoassay Analyzers, with initial efforts targeting the DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers. Fujirebio has obtained FDA authorization for β-amyloid pathology assessment using cerebral spinal fluid and is continuing to develop and expand the menu with additional biomarkers obtained through the recent acquisition of ADx NeuroSciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
partnership
-
News

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test

Rhea-AI Summary
Fujirebio and Beckman Coulter Diagnostics announce a partnership to develop blood-based diagnostic capabilities for neurodegenerative diseases, addressing the global unmet clinical need for Alzheimer's Disease diagnostics. The collaboration leverages Fujirebio's expertise in neurodegenerative disease assays and Beckman Coulter's high sensitivity, high throughput, global installed base of Access Family of Immunoassay Analyzers. This partnership aims to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases, with a focus on Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
partnership
News

Danaher Schedules Second Quarter 2023 Earnings Conference Call

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
earnings

FAQ

What is the current stock price of Danaher Corporation (DHR)?

The current stock price of Danaher Corporation (DHR) is $230.75 as of December 24, 2024.

What is the market cap of Danaher Corporation (DHR)?

The market cap of Danaher Corporation (DHR) is approximately 166.7B.

What does Danaher Corporation specialize in?

Danaher Corporation specializes in designing, manufacturing, and marketing medical, industrial, and commercial products, with a focus on life sciences and diagnostics.

Who founded Danaher Corporation and when?

Danaher Corporation was founded by brothers Stephen and Mitchell Rales in 1984.

Where is Danaher Corporation headquartered?

Danaher Corporation is headquartered in Washington, D.C.

What recent divestiture has Danaher Corporation made?

In late 2023, Danaher Corporation divested its environmental and applied solutions group, Veralto.

What are some of Danaher's notable subsidiaries?

Notable subsidiaries of Danaher include Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron.

What recent acquisition has enhanced Danaher's capabilities in proteomics?

The acquisition of Abcam plc has enhanced Danaher's capabilities in the proteomics market.

What is the Danaher Beacons program?

The Danaher Beacons program funds pioneering academic research to develop innovative medical technologies and applications.

What collaboration is Danaher involved in to improve liver organoid technology?

Danaher is collaborating with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening.

What is the focus of Danaher's partnership with Johns Hopkins University?

Danaher and Johns Hopkins University are working together to develop methods for diagnosing mild traumatic brain injuries using advanced biomarker panels.

How does Danaher contribute to the field of gene-editing therapies?

Danaher contributes to gene-editing therapies through a collaboration with the Innovative Genomics Institute to develop CRISPR-based treatments for various diseases.

Stock DHR logo
Danaher Corporation

NYSE:DHR

DHR Rankings

#68 Ranked by Market Cap
#2034 Ranked by Dividends

DHR Stock Data

166.66B
642.71M
11%
81.45%
0.7%
Diagnostics & Research
Industrial Instruments for Measurement, Display, and Control
Link
United States of America
WASHINGTON